Rice Hall James & Associates LLC acquired a new position in shares of Aimmune Therapeutics Inc (NASDAQ:AIMT) during the 1st quarter, HoldingsChannel reports. The firm acquired 510,709 shares of the biotechnology company’s stock, valued at approximately $11,414,000.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in AIMT. Proficio Capital Partners LLC bought a new stake in Aimmune Therapeutics during the fourth quarter worth approximately $96,000. Carroll Financial Associates Inc. bought a new stake in Aimmune Therapeutics during the fourth quarter worth approximately $28,000. Caption Management LLC boosted its holdings in Aimmune Therapeutics by 313.3% during the fourth quarter. Caption Management LLC now owns 24,800 shares of the biotechnology company’s stock worth $593,000 after buying an additional 18,800 shares in the last quarter. Emerald Advisers LLC boosted its holdings in Aimmune Therapeutics by 52.4% during the fourth quarter. Emerald Advisers LLC now owns 741,746 shares of the biotechnology company’s stock worth $17,743,000 after buying an additional 255,080 shares in the last quarter. Finally, Jane Street Group LLC boosted its holdings in Aimmune Therapeutics by 141.4% during the third quarter. Jane Street Group LLC now owns 19,072 shares of the biotechnology company’s stock worth $520,000 after buying an additional 11,172 shares in the last quarter. Hedge funds and other institutional investors own 73.74% of the company’s stock.

Aimmune Therapeutics stock traded down $0.07 during midday trading on Friday, reaching $19.72. The stock had a trading volume of 519,924 shares, compared to its average volume of 608,094. Aimmune Therapeutics Inc has a twelve month low of $19.52 and a twelve month high of $36.12. The firm has a market capitalization of $1.23 billion, a price-to-earnings ratio of -5.37 and a beta of -0.19.

A number of analysts recently weighed in on AIMT shares. Wedbush restated a “buy” rating and set a $80.00 target price on shares of Aimmune Therapeutics in a report on Tuesday, February 26th. Credit Suisse Group reaffirmed a “buy” rating and issued a $40.00 price objective on shares of Aimmune Therapeutics in a research note on Tuesday, January 15th. Cantor Fitzgerald set a $45.00 price objective on shares of Aimmune Therapeutics and gave the stock a “buy” rating in a research note on Thursday, February 28th. ValuEngine lowered shares of Aimmune Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, February 4th. Finally, Zacks Investment Research raised shares of Aimmune Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, February 4th. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the company’s stock. Aimmune Therapeutics currently has an average rating of “Hold” and an average target price of $47.13.

COPYRIGHT VIOLATION NOTICE: “Rice Hall James & Associates LLC Invests $11.41 Million in Aimmune Therapeutics Inc (AIMT) Stock” was first posted by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/rice-hall-james-associates-llc-invests-11-41-million-in-aimmune-therapeutics-inc-aimt-stock/2997606.html.

Aimmune Therapeutics Profile

Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy.

See Also: Blue-Chip Stocks

Want to see what other hedge funds are holding AIMT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aimmune Therapeutics Inc (NASDAQ:AIMT).

Institutional Ownership by Quarter for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.